Key result
Transcatheter aortic valve replacement is an established first-line treatment for high-risk surgical patients with severe aortic stenosis, while its application in intermediate and low-risk patients continues to evolve.
Why the study?
While surgical replacement has complications and transcatheter intervention is gaining recognition, comparative outcomes across different surgical risk categories require ongoing evaluation.
Does transcatheter aortic valve replacement improve outcomes compared to surgical aortic valve replacement in patients with severe symptomatic aortic stenosis?
Does transcatheter aortic valve replacement improve outcomes compared to surgical aortic valve replacement in patients with severe symptomatic aortic stenosis?
This review affirms TAVR as the procedure of choice for high-risk surgical patients with severe symptomatic aortic stenosis, while highlighting the need for further evidence in lower-risk populations.
TAVR expands treatment options across AS risk strata; extends RCT evidence to evolving indications.
Patients with severe symptomatic aortic stenosis (AS) are categorized into high risk, intermediate risk, and low risk. The identification of risk status is done using the Society of Thoracic Surgeons mortality score. Various factors are considered such as clinical symptoms, ejection fraction, age, left ventricle measurements, severity of AS, associated comorbid factors, and any other associated cardiac diseases. Surgery is still a standard practice in many countries. However, it has its own complications, especially in high-risk patients. Transcatheter intervention is getting precipitous recognition as an alternative mode of treatment in selected cases to mitigate complication rates and improve quality of life. In this article, transcatheter aortic valve replacement and surgical aortic valve replacement are compared in patients with different surgical risks. The impact of the cost of the procedure and quality of life are of paramount importance in choosing the type of intervention. Structural valve degeneration is an independent risk factor affecting patient outcomes. Modifications in valve designs are being constantly implemented as well. The standard analytical methods are in accordance with randomized clinical trials to determine the efficacy and outcome of procedures. Primary and secondary endpoints were considered to evaluate the data. The results were tabulated to derive statistical significance of the studies. In high-risk surgical patients, transcatheter intervention has been proven as the procedure of choice for valve replacement. However, intermediate-risk and low-risk categories need further studies.
No takes yet. Share an insight, caveat, or question.
Shrivastava et al. (2022) conducted a review in Severe symptomatic aortic stenosis. Transcatheter Aortic Valve Replacement (TAVR) vs. Surgical Aortic Valve Replacement (SAVR) was evaluated. Transcatheter aortic valve replacement is an established first-line treatment for high-risk surgical patients with severe aortic stenosis, while its application in intermediate and low-risk patients continues to evolve.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: